Sam Fazeli
Director of research for global industries at Bloomberg Intelligence who discusses healthcare and pharma topics, including Pfizer's acquisition of Metsera and obesity-drug science.
Best podcasts with Sam Fazeli
Ranked by the Snipd community
15 snips
Aug 26, 2025 • 23min
AT&T to Buy EchoStar Spectrum Licenses for About $23 Billion
Sam Fazeli, a pharmaceutical industry expert at Bloomberg Intelligence, discusses Eli Lilly's groundbreaking weight-loss pill, revealing that participants lost an impressive 9.6% of their body weight in trials. Meanwhile, Patricio Alvarez, specializing in Power & Gas Utilities, highlights the regulatory challenges Orsted faces after a construction halt on its offshore wind farm. The conversation also touches on AT&T's $23 billion acquisition of spectrum licenses from EchoStar, exploring its implications for the telecom industry and competition.
Sep 22, 2025 • 23min
TikTok’s Algorithm to Be Secured by Oracle in Trump-Backed Deal
Sam Fazeli, Director of Research for Global Industries at Bloomberg Intelligence, unpacks Pfizer's ambitious $4.9 billion acquisition of Metsera, aimed at tapping into the booming obesity market. He compares Metsera's long-acting amylin analogs with existing GLP-1 treatments, highlighting efficacy and side effects. The discussion also touches on the impact of H-1B visa costs on pharmaceutical talent. With a deep dive into healthcare innovation, Fazeli’s insights paint a vivid picture of the evolving landscape in obesity treatment.
